Jun 2026 (Q3 FY26) — Aug 5, 2026
Azenta Q3 FY26 — Revenue Exceeds Outlook, Multiomics Turnaround Underway
Read the full callAzenta (AZTA) earnings
- Jun 2026
- Jun 2026 (Q3 FY26)
- Sep 2025
Azenta earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 161 | +12.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -2.6 | −1.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 2.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$34.84 +2.20% · +$0.75
Performance +12.5% 1Y
1Y: $30.97 on 17 Oct 2025 → $34.84. High $42.73 (5 Oct 2026), low $16.02 (15 May 2026).
- Previous close
- $34.09
- 52-week range
- $16.02 – $42.73
- One year
- +10.36%
Overview
- Symbol
- AZTA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Azenta earnings calls (AZTA)
Financials
What the filings say
Net profit, year on year: +105% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 151 | 147 | 143 | 144 | 159 | 149 | 145 | 161 |
| Operating profit | -5 | -9 | -18 | -2 | 2 | -7 | -166 | -4 |
| Operating margin | −3.1% | −5.9% | −12.7% | −1.3% | 1.2% | −4.9% | −114.5% | −2.6% |
| Profit before tax | 0 | -3 | -13 | 2 | 6 | -2 | -157 | 1 |
| Tax rate | 699.7% | −121.1% | −57.7% | 114.4% | −719.9% | −151.9% | 0.2% | 280.7% |
| Net profit | -7 | -11 | -48 | -48 | 51 | -15 | -161 | 2 |
| EPS ($ per share) | -0.14 | -0.25 | -1.04 | -1.05 | 1.11 | -0.34 | -3.49 | 0.05 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -994 | -586 | -551 | -470 | 1,655 | 1,641 | 1,476 | 1,420 |
| Total liabilities | 377 | 377 | 346 | 494 | 353 | 351 | 332 | 333 |
| Fixed assets | 60 | 101 | 89 | 131 | 154 | 206 | 156 | 154 |
| Total assets | 1,095 | 1,516 | 1,559 | 1,820 | 3,716 | 2,885 | 2,100 | 2,060 |
| Line item | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 74 | 91 | 38 | 150 | -466 | 6 | 50 | 72 |
| Cash from investing | -148 | 211 | -23 | -146 | 1,466 | 431 | 225 | -90 |
| Cash from financing | 170 | -191 | -27 | -26 | -63 | -840 | -659 | -10 |
| Net cash flow | 96 | 107 | -3 | -17 | 756 | -357 | -363 | -24 |
| Capital expenditure | -13 | -24 | -40 | -53 | -73 | -39 | -37 | -34 |
| Free cash flow | 61 | 67 | -2 | 97 | -539 | -34 | 12 | 38 |
Insider filings
26 filings between Nov 14, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
$171.9K
2 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 17
- Award — granted as compensation
- 7
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Cornog William L | $163.8K | — | May 18, 2026 |
| Starr Ephraim | $8.1K | — | Jul 31, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Madaus Martin D Interim CEO | Tax withheld | 1,456 | $49.9K |
| Sep 15, 2026 | Bello Erik J. VP Chief Accounting Officer | Award | 4,586 | $0 |
| Sep 14, 2026 | Madaus Martin D Interim CEO | Award | 36,653 | $0 |
| Sep 14, 2026 | Lin Lawrence Y. EVP, CFO and Treasurer | Award | 30,544 | $0 |
| Sep 14, 2026 | Starr Ephraim SVP, Gen Counsel & Secretary | Award | 15,272 | $0 |
| Sep 14, 2026 | Pirogova Olga SVP and CHRO | Award | 15,272 | $0 |
| Sep 14, 2026 | MARTIN WILLIAM E. III President Multiomics | Award | 15,272 | $0 |
| Aug 9, 2026 | Pirogova Olga SVP and CHRO | Tax withheld | 1,085 | $34.8K |
| Jul 31, 2026 | Starr Ephraim SVP, Gen Counsel & Secretary | Purchase | 335 | $8.1K |
| May 18, 2026 | Cornog William L Director | Purchase | 10,000 | $163.8K |
| May 15, 2026 | Starr Ephraim SVP, Gen Counsel & Secretary | Tax withheld | 3,621 | $58.0K |
| Apr 28, 2026 | MARTIN WILLIAM E. III President Multiomics | Award | 17,790 | $431.2K |
| Feb 6, 2026 | Nova Tina Susan Director | Award | 5,663 | $157.7K |
| Feb 5, 2026 | Koffey Quentin Director | Award | 5,663 | $0 |
| Feb 5, 2026 | McLaughlin Erica Director | Award | 5,663 | $157.7K |
| Feb 5, 2026 | Casal Frank Director | Award | 7,243 | $201.7K |
| Feb 5, 2026 | Doshi Dipal Director | Award | 5,663 | $157.7K |
| Nov 24, 2025 | Marotta John President and CEO | Award | 118,194 | $0 |
| Nov 24, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Award | 36,681 | $0 |
| Nov 24, 2025 | Starr Ephraim SVP, Gen Counsel & Secretary | Award | 34,235 | $0 |
| Nov 24, 2025 | Zhou Ginger SVP and GM, Multiomics | Award | 13,042 | $0 |
| Nov 24, 2025 | Pirogova Olga SVP and CHRO | Award | 16,303 | $0 |
| Nov 14, 2025 | Marotta John President and CEO | Tax withheld | 10,980 | $326.7K |
| Nov 14, 2025 | Zhou Ginger SVP and GM, Multiomics | Tax withheld | 1,118 | $33.3K |
| Nov 14, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Tax withheld | 3,039 | $90.4K |
| Nov 14, 2025 | Pirogova Olga SVP and CHRO | Tax withheld | 1,553 | $46.2K |
| Sep 10, 2025 | Marotta John President and CEO | Sale | 316 | $9.3K |
| Aug 12, 2025 | Zhou Ginger SVP and GM, Multiomics | Sale | 1,085 | $31.0K |
| Aug 12, 2025 | Pirogova Olga SVP and CHRO | Sale | 1,085 | $31.0K |
| Aug 11, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Purchase | 2,500 | $69.9K |
| Jun 2, 2025 | Marotta John President and CEO | Purchase | 1,000 | $26.0K |
| May 30, 2025 | Malus Alan J Director | Purchase | 12,000 | $319.8K |
| May 20, 2025 | Cornog William L Director | Purchase | 2,748 | $75.2K |
| May 19, 2025 | Cornog William L Director | Purchase | 4,152 | $112.0K |
| May 16, 2025 | Cornog William L Director | Purchase | 100 | $2.6K |
| May 15, 2025 | Starr Ephraim SVP, Gen Counsel & Secretary | Award | 37,779 | $1.01M |
| May 9, 2025 | Marotta John President and CEO | Award | 1,796 | $49.4K |
| May 9, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Award | 4,000 | $110.0K |
| May 8, 2025 | Marotta John President and CEO | Award | 3,638 | $100.0K |
| May 8, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Award | 2,000 | $55.3K |
| Feb 11, 2025 | Lin Lawrence Y. EVP, CFO and Treasurer | Award | 2,200 | $101.2K |
| Feb 7, 2025 | Davis Robyn C Director | Award | 4,040 | $211.4K |
| Feb 7, 2025 | McLaughlin Erica Director | Award | 4,040 | $211.4K |
| Feb 7, 2025 | Doshi Dipal Director | Award | 4,040 | $211.4K |
| Feb 7, 2025 | Nova Tina Susan Director | Award | 4,040 | $211.4K |
| Feb 7, 2025 | Casal Frank Director | Award | 5,168 | $270.4K |
| Feb 7, 2025 | Malus Alan J Director | Award | 4,040 | $211.4K |
| Feb 7, 2025 | Koffey Quentin Director | Award | 4,040 | $0 |
| Feb 3, 2025 | Hughes Violetta VP, Chief Accounting Officer | Sale | 317 | $16.8K |
| Jan 31, 2025 | Zhou Ginger SVP and General Manager, Genom | Purchase | 417 | $19.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Azenta, Inc.
Free account. Everything above stays public.
Write why you follow Azenta, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading